CABA-201
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Myasthenia Gravis (gMG)
Conditions
Generalized Myasthenia Gravis (gMG)
Trial Timeline
Dec 17, 2024 → Sep 1, 2029
NCT ID
NCT06359041About CABA-201
CABA-201 is a phase 1/2 stage product being developed by Cabaletta Bio for Generalized Myasthenia Gravis (gMG). The current trial status is active. This product is registered under clinical trial identifier NCT06359041. Target conditions include Generalized Myasthenia Gravis (gMG).
What happened to similar drugs?
6 of 20 similar drugs in Generalized Myasthenia Gravis (gMG) were approved
Approved (6) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
9
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07006805 | Phase 1/2 | Recruiting |
| NCT06359041 | Phase 1/2 | Active |
| NCT06328777 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Generalized Myasthenia Gravis (gMG)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 35 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 29 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |